Kymera Therapeutics (NASDAQ: KYMR) received a $45 million milestone payment from Gilead Sciences after Gilead exercised its option to exclusively license Kymera’s oral CDK2 molecular‑glue degrader, KT‑200. The payment, announced on April 9 2026, is the first of a series of milestone and royalty payments that could total up to $750 million under the collaboration agreement.
KT‑200 is a first‑in‑class oral CDK2 degrader that removes the protein rather than merely inhibiting it, offering a new therapeutic strategy for cancers that have become resistant to CDK4/6 inhibitors. The partnership with Gilead validates Kymera’s molecular‑glue platform and expands its oncology portfolio, positioning the company to pursue IND‑enabling studies that could lead to a 2027 IND filing.
The $45 million infusion boosts Kymera’s cash position, extending its runway into the first half of 2028. At the end of 2025, Kymera reported $775 million in cash, cash equivalents, and investments, and the company’s cash balance is now projected to reach roughly $1.6 billion, providing a buffer for ongoing development of its STAT6 and IRF5 immunology programs.
Beyond the milestone, the collaboration includes upfront payments of $40 million at signing, bringing total payments to $85 million to date, and potential tiered royalties on future sales. Kymera’s management has indicated that the partnership will support continued investment in its pipeline, including the STAT6 (KT‑621) and IRF5 (KT‑579) programs, and will help the company maintain a strong balance sheet for future clinical milestones.
"We are excited to have reached this key milestone in our strategic collaboration with Gilead, underscoring our commitment to advancing a new generation of medicines for patients through our innovative discovery engine," said Nello Mainolfi, PhD, founder, president and CEO of Kymera. "KT‑200 is expected to be the first molecular glue discovered by Kymera to enter the clinic, reflecting the company’s ability to apply our discovery capabilities to some of the most challenging disease‑causing targets."
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.